| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 24 Jul 2024 | 17 Jul 2024 |
| BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/07/2024 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30 2024. Further according to SEBI (Prohibition of Insider Trading) Regulations 2015 and the Companys Code of Internal Procedures and Conduct for Regulating Monitoring and Reporting of Trading by Designated Persons the trading window for dealing in shares of the Company was closed for all the Designated Persons and their immediate relatives of the Company from July 01 2024 and shall remain closed till 48 hours after the announcement/declaration of Unaudited Financial Results of the Company for the quarter ended June 30 2024. Please find attached herewith the Outome of Board Meeting held on today i.e. July 24, 2024 for approval of Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2024. (As per BSE Announcement Dated on 24/07/2024) | ||
| Board Meeting | 2 May 2024 | 25 Apr 2024 |
| BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/05/2024 inter alia to consider and approve a) To consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31 2024 along with the Statement of Assets and Liabilities Cash Flow Statement and take note of the Audit Report with modified opinion if any thereon; b) To consider and approve the Audited Standalone and Consolidated Financial Statement of the Company for the financial year ended March 31 2024; and c) To discuss and recommend the Final Dividend if any for the financial year ended March 31 2024. We would like to inform you that, the Board Meeting of the Company was held today i.e. Thursday, May 02, 2024 at the registered office of the Company. In pursuant to Regulation 30 and Regulation 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has considered and approved the matters amongst others as attached. Please find attached herewith Outcome of the Board Meeting held on May 02, 2024. Recommended Final Dividend of 50% i.e. 50 Paisa per equity share on the face value of Rs. 1/- each for the financial year ended March 31, 2024, subject to the approval of the shareholders in the forthcoming 39th Annual General Meeting of the Company. (As Per BSE Announcement Dated on 02.05.2024) | ||
| Board Meeting | 16 Feb 2024 | 16 Feb 2024 |
| The Board of Directors of the Company has approved an internal restruturing of foreign subsidiaries of the Company. | ||
| Board Meeting | 23 Jan 2024 | 16 Jan 2024 |
| BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/01/2024 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31 2023. Further pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 and the Companys Code of Internal Procedures and Conduct for Regulating Monitoring and Reporting of Trading by Designated Persons the trading window for dealing in shares of the Company was closed for all the Designated Persons of the Company and their immediate relatives of the Company from January 01 2024 and shall remain closed until 48 hours after the announcement of Unaudited Financial Results of the Company for the quarter and nine months ended December 31 2023. Enclosed herewith the outcome of board meeting held on January 23, 2024 (As Per BSE Announcement Dated on 23.01.2024) | ||
| Board Meeting | 1 Nov 2023 | 25 Oct 2023 |
| BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/11/2023 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year September 30 2023. Further pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 and the Companys Code of Internal Procedures and Conduct for Regulating Monitoring and Reporting of Trading by Designated Persons the trading window for dealing in shares of the Company was closed for all the Designated Persons of the Company and their immediate relatives of the Company from October 01 2023 and shall remain closed until 48 hours after the announcement of unaudited Financial Results of the Company for the quarter and half year September 30 2023. We would like to inform you that the Board Meeting of the Company was held today i.e. Wednesday, November 01, 2023, at the registered office of the Company. In pursuant to Regulation 30 and Regulation 33 read with Schedule III of SEBI Listing Regulations. Enclosed herewith Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2023 along with Limited Review Report. We would like to inform you that the Board Meeting of the Company was held today i.e. Wednesday, November 01, 2023, at the registered office of the Company. In pursuant to Regulation 30 and Regulation 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has considered and approved the following matters amongst others: 1. The Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2023. 2. Investment of INR 30 Crores (Approx.) for Capacity Addition/Inclusion of Semi-Solids Finished formulation at our Palghar Vevoor Unit. The Total Capacity expected is approx. 200 million Units in Semi-Solids Dosage and that is expected to be completed and available for commercial production by end of F. Y 2025-26. This expansion shall be funded by a combination of debt and internal accrual. (As per BSE Announcement Dated on 01/11/2023) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice
